Table 4.
Actual and hypothetical duration of antimicrobial therapy and hospital length-of-stay (LOS) in 50 patients with different Gram-positive infections.
| Variables | Total (n = 50) | ABSSSIs (n = 12) | Complicated ABSSSIs (n = 8) | Bone and joints infections (n = 18) | CIED/vascular grafts infections (n = 12) | p value |
|---|---|---|---|---|---|---|
| Duration of antimicrobial therapy [days/patient, median (IQR)] | ||||||
| Prior to dalbavancin therapy | 10 (4–23) | 2 (2–4) | 12 (5–32) | 18 (16–32) | 13 (8–28) | < 0.001 |
| After switch to dalbavancina | 14 (14–42) | 14 (14–14) | 28 (28–56) | 14 (14–42) | 42 (14–42) | 0.033 |
| Hospital LOS [days/patient, median (IQR)]b | ||||||
| Actual | 22 (11–33) | 13 (10–23) | 12 (6–25) | 28 (19–38) | 21 (14–33) | 0.053 |
| Hypotheticalc | 47 (35–67) | 30 (24–42) | 58 (41–68) | 50 (40–74) | 55 (35–76) | 0.009 |
| Reduction in hospital LOS | 14 (14–49) | 14 (14–14) | 28 (28–42) | 21 (21–49) | 42 (14–42) | 0.015 |
ABSSSIs acute bacterial skin and skin structure infections, CIED cardiac implantable electronic device, IQR interquartile range
aEnd of dalbavancin therapy has been considered to be at 14 days after the last 1500 mg dalbavancin dose (see text, Sect. 2.1 “Definitions” paragraph)
bOverall length of stay since hospital admission, which included the time period prior to start of antimicrobial therapy and was possibly influenced by other clinical problems other than the infection
cHypothetical duration of hospitalization was estimated considering that the initial standard antimicrobial treatment would have been administered in hospital, without switching to dalbavancin, until the end of therapy (see text, “Methods” Sect. 2)